A
Agilent Technologies, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow -0.2% ·
net new positions -6.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 152.88K | $24.44M | n/a | −3 |
| Q2 2026 | 164 | +3 | 194.45M | $25.84B | +9 | −7 |
| Q1 2026 | 165 | -3 | 181.10M | $20.68B | +3 | −7 |
| Q4 2025 | 167 | +1 | 200.20M | $27.23B | +3 | −1 |
| Q3 2025 | 22 | +2 | 109.95M | $14.10B | +3 | −2 |
| Q2 2025 | 18 | -1 | 102.37M | $12.08B | n/a | −1 |
| Q1 2025 | 16 | -1 | 41.13M | $4.81B | n/a | −1 |
| Q4 2024 | 17 | +1 | 41.24M | $5.54B | +2 | −1 |
| Q3 2024 | 15 | -1 | 26.67M | $3.96B | +1 | −2 |
| Q2 2024 | 16 | n/a | 29.82M | $3.86B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 12.61M | -0.8% | $1.48B | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.93M | -4.0% | $1.04B | 0.2% | ▼ Trim | 4 | SEC ↗ ×8 |
| 3 | Geode Capital Management ✦ (passive) | 7.20M | +2.9% | $840.05M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 3.42M | +0.6% | $400.13M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 2.10M | +130.6% | $245.41M | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 1.90M | +2.4% | $222.84M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 1.54M | -14.1% | $179.82M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Marshall Wace ✦ | 1.47M | +82.0% | $171.80M | 0.2% | ▲ Add | 4 | SEC ↗ ×4 |
| 9 | T. Rowe Price ✦ | 527.42K | -52.1% | $61.70M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 411.15K | -46.6% | $48.10M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 389.58K | -10.1% | $44.79M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
| 12 | D. E. Shaw & Co. ✦ | 262.27K | +586.5% | $30.68M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 257.28K | +17.8% | $30.10M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 70.07K | -90.3% | $8.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 38.77K | -73.9% | $4.54M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 4.42K | -22.5% | $517,637 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Fisher Asset Management | $664,764 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,065 holders, 251.21M shares, $26.86B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 634 sh · $95,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology